PGP(20:4(5Z,8Z,11Z,14Z)/18:0) (BioCAD00000110705)
{$topic}
Metabolite Card
Formula: C44H80O13P2 (878.5074)
SMILES: [H][C@](O)(COP(O)(O)=O)COP(O)(=O)OC[C@@]([H])(COC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC)OC(=O)CCCCCCCCCCCCCCCCC
Synonyms [en]
PGP(20:4(5Z,8Z,11Z,14Z)/18:0); PGP(20:4w6/18:0) ; PGP(20:4/18:0); [(2S)-2-Hydroxy-3-({hydroxy[(2R)-3-[(5Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]-2-(octadecanoyloxy)propoxy]phosphoryl}oxy)propoxy]phosphonate; PGP(20:4n6/18:0) ; PGP(20:4/18:0)
Last reviewed on 2024-06-28.
Cite this Page
PGP(20:4(5Z,8Z,11Z,14Z)/18:0). 数据之源,洞见之始. SMRUCC genomics institute, a synthetic life researcher from China.
https://biocad_registry.innovation.ac.cn/s/(-)-arctiin
(retrieved
2026-01-03) (CAD Registry RN: BioCAD00000110705). Licensed
under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Note
PGP(20:4(5Z,8Z,11Z,14Z)/18:0) is a phosphatidylglycerophosphate (PGP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site followed by another phosphate moiety. Phosphatidylglycerolphosphate is present at a level of 1-2% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11% of the total). It is well established that the concentration of phosphatidylglycerolphosphate increases during fetal development. Phosphatidylglycerolphosphate may be present in animal tissues merely as a precursor for cardiolipin synthesis. As is the case with diacylglycerols, phosphatidylglycerophosphates can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PGP(20:4(5Z,8Z,11Z,14Z)/18:0), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of stearic acid at the C-2 position. They are synthesized by the addition of glycerol 3-phosphate to a CDP-diacylglycerol. In turn, PGPs are dephosphorylated to phosphatidylglycerols (PGs). While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes.
DBLinks
- CAS Registry Number:
- PubChem CID: 131823137
- ChEBI:
- HMDB: HMDB0116482
- LipidMaps:
- KEGG:
- BioCyc:
- NCBI MeSH:
- Wikipedia:
Other DBLinks
- PubChem: 131823137
- HMDB: HMDB0116482
Class / Ontology
- WishartLab ClassyFire: [Glycerophosphoglycerophosphates] Glycerophosphoglycerophosphates
Taxonomy Source
Pathway Synthetic
| pathway id | name |
|---|---|
| PathBank:SMP0029619 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z)/18:1(9Z)) |
| PathBank:SMP0029623 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)) |
| PathBank:SMP0029627 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)) |
| PathBank:SMP0029631 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)) |
| PathBank:SMP0029635 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) |
| PathBank:SMP0072030 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z)/16:1(9Z)) |
| PathBank:SMP0072034 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z)/18:1(9Z)) |
| PathBank:SMP0072038 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z)) |
| PathBank:SMP0072043 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z)) |
| PathBank:SMP0072047 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)) |
| PathBank:SMP0072051 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0) |
| PathBank:SMP0079814 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z)/16:1(9Z)) |
| PathBank:SMP0079818 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z)) |
| PathBank:SMP0079822 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) |
| PathBank:SMP0079826 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z)) |
| PathBank:SMP0079830 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(7Z,10Z,13Z,16Z,19Z)) |
| PathBank:SMP0095090 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z)/18:1(9Z)) |
| PathBank:SMP0095094 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)) |
| PathBank:SMP0095098 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)) |
| PathBank:SMP0095102 | Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/18:0/22:5(7Z,10Z,13Z,16Z,19Z)/22:5(4Z,7Z,10Z,13Z,16Z)) |